By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous bone resorption inhibitors > Evenity > Evenity Side Effects
Miscellaneous bone resorption inhibitors

Evenity Side Effects

Note: This document contains side effect information about romosozumab. Some dosage forms listed on this page may not apply to the brand name Evenity.

Applies to romosozumab: subcutaneous solution.

Warning

Subcutaneous route (Injectable)

Warning: Potential Risk of Myocardial Infarction, Stroke and Cardiovascular DeathRomosozumab-aqqg may increase the risk of myocardial infarction, stroke, and cardiovascular death.Romosozumab-aqqg should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors.If a patient experiences a myocardial infarction or stroke during therapy, romosozumab-aqqg should be discontinued.

Serious side effects of Evenity

Along with its needed effects, romosozumab (the active ingredient contained in Evenity) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking romosozumab:

More common

  • Fast heartbeat
  • fever
  • hives, itching, skin rash
  • hoarseness
  • irritation
  • joint pain, stiffness, or swelling
  • redness of the skin
  • swelling of the eyelids, face, lips, hands, or feet
  • tightness in the chest
  • troubled breathing or swallowing

Less common

  • Large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
  • rapid weight gain
  • tingling of the hands or feet
  • unusual weight gain or loss

Rare

  • Chest pain or discomfort
  • confusion
  • difficulty in breathing
  • difficulty in speaking
  • double vision
  • headache
  • heavy jaw feeling
  • inability to move the arms, legs, or facial muscles
  • inability to speak
  • irregular heartbeat
  • limp
  • loosening of a tooth
  • mood or mental changes
  • muscle cramps in the hands, arms, feet, legs, or face
  • nausea
  • numbness and tingling around the mouth, fingertips, or feet
  • pain or discomfort in the arms, jaw, back, or neck
  • pain, swelling, or numbness in the mouth or jaw
  • pain, swelling, tenderness, and bruising in your thigh
  • seizures
  • slow speech
  • stomach cramps
  • sweating
  • tremor
  • vomiting

Other side effects of Evenity

Some side effects of romosozumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Difficulty in moving
  • muscle pain or stiffness

Less common

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • lack or loss of strength
  • trouble sleeping

For Healthcare Professionals

Applies to romosozumab: subcutaneous solution.

General

The most commonly reported adverse reactions have included arthralgia and headache.[Ref]

Cardiovascular

During clinical trials, this drug increased the risk of cardiovascular death, heart attack and stroke in the compared with alendronate, but not compared with placebo; myocardial infarction occurred in 16 (0.8%) women receiving this drug compared to 5 (0.2%) receiving alendronate and stroke in 13 (0.5%) and 7 (0.3%) patients receiving this drug and alendronate, respectively. These events occurred in women with and without a history of MI or stroke. Cardiovascular death occurred in 17 (0.8%) and 12 (0.6%) of patients receiving this drug and alendronate, respectively. Positively adjudicated MACE (major adverse cardiac events; composite endpoint of cardiovascular death, nonfatal MI and nonfatal stroke) was significantly different at 41 (2%) and 22 (1.1%) in patients receiving this drug and alendronate respectively.

In the placebo-controlled trial, the number of women with positively adjudicated MACE was not significantly different with both groups reporting 0.8%.

Common (1% to 10%): Peripheral edema

Uncommon (0.1% to 1%): Myocardial infarction, myocardial death

Nervous system

Nervous system

Common (1% to 10%): Headache, paresthesia

Uncommon (0.1% to 1%): Stroke

During clinical trials, this drug increased the risk of cardiovascular death, heart attack and stroke in the alendronate trial, but not in the placebo trial; myocardial infarction occurred in 16 (0.8%) women receiving this drug compared to 5 (0.2%) receiving alendronate and stroke in 13 (0.5%) and 7 (0.3%) of patients receiving this drug and alendronate, respectively. These events occurred in women both with and without a history of MI or stroke. Positively adjudicated MACE (major adverse cardiac events; composite endpoint of cardiovascular death, nonfatal MI and nonfatal stroke) was significantly different at 41 (2%) and 22 (1.1%) in patients receiving this drug and alendronate respectively.

In the placebo-controlled trial, the number of women with positively adjudicated MACE was not significantly different with both groups reporting 0.8%.

Hypersensitivity

Common (1% to 10%): Hypersensitivity reactions (angioedema, erythema multiforme, dermatitis, rash, urticaria)

Hypersensitivity reactions were reported in 6.5% of women in clinical trials; reactions included angioedema and erythema multiforme in less than 0.1%, dermatitis (0.6%), rash (1.1%), and urticaria (0.4%).

Local

Common (1% to 10%): Injection site reactions

Injection site reactions occurred in 278 (4.9%) of patients and included injection site pain (1.7%) and erythema (1.4%).

Musculoskeletal

Osteonecrosis of the jaw occurred in 1 patient receiving this drug during clinical trials. Atypical femoral fracture also occurred in 1 patient.

Very common (10% or more): Arthralgia (up to 13.1%)

Common (1% to 10%): Muscle spasms, neck pain

Very rare (less than 0.01%): Osteonecrosis of the jaw, atypical femoral fracture

Other

Common (1% to 10%): Asthenia

Psychiatric

Common (1% to 10%): Insomnia

Immunologic

During clinical trials, 18.1% of the 5914 postmenopausal women receiving this drug developed antibodies; 4.7% had antibodies classified as neutralizing. Development of antibodies was associated with lower serum drug concentrations, however, was not associated with changes in safety and efficacy.

Very common (10% or more): Anti-drug antibodies (18.1%)

Metabolic

Uncommon (0.1% to 1%): Hypocalcemia

In clinical trials, 2 women receiving this drug experienced hypocalcemia. Decreases in albumin adjusted serum calcium to less than 8.3 mg/dL were reported in 14 (0.2%) women; there were no reports of adjusted serum calcium less than 7.5 mg/dL. The nadir in albumin-adjusted serum calcium occurred by month 1 in patients with normal renal function.

Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by